Overview

COSA's CPG Fellowship program has been established to address strategic priorities while mentoring and supporting the development of promising early career researchers. Fellows receive mentorship, guidance and support from the CPG Executive Committee.

Details on this project

COSA's Cancer Pharmacists Group (CPG) is calling for expressions of interest from early career researchers to become a COSA Cancer Pharmacists Group Fellow.

The Fellowship is being offered through the COSA Cancer Pharmacists Group's Fellowship program which has been developed to address strategic priorities while providing mentorship and support to promising early career researchers.

The Fellow will lead the project to develop a COSA Position Statement, endorsed by the CPG Executive and COSA Council, on the Documentation of hypersensitivity reactions to systemic anticancer therapy (SACT), to support safe, consistent, and high-quality practice across Australian cancer services.

The successful Fellow will be mentored by A/Prof Marissa Ryan and A/Prof Marliese Alexander. Additional mentorship will be provided by other COSA members.

The time commitment for this project is 4-8 hours a week for approximately 12 months. Before submitting an application, applicants are expected to confirm that their current manager/supervisor supports them dedicating the time required to undertake the Fellowship. This role is voluntary in nature, there is no financial reimbursement. If not already a COSA member, the successful applicant would be expected to join COSA and become a member of the Cancer Pharmacists Group.

Key activities are likely to include:

- Formation of a Steering Committee comprising:

Nationally representative cancer pharmacy and oncology stakeholders
Key international experts to provide global perspectives

- Scoping literature review:

To identify current evidence, guidelines, and international standards for hypersensitivity reaction documentation in cancer care

- National practice review:

To assess current documentation practices across Australian institutions, including systems used, triggers for documentation, and clinical handover processes

- Position statement development:

Synthesising findings into a draft position statement for review and endorsement by the COSA Cancer Pharmacists Group, COSA Council and any other relevant national partners

Depending on final contribution, the successful applicant will:

1. 1. act as the first author of a peer reviewed manuscript resulting from this work
   2. receive a complimentary registration to present this work at the COSA ASM
   3. attend and participate in at least one CPG training course (registration funded by COSA) – participant vs presenter vs convenor role to be confirmed based on Fellow's experience
   4. be encouraged to present the work at other meetings and conferences receive a certificate of acknowledgement

Please provide your brief expression of interest to [email protected] by COB Friday 3 October 2025 (i) briefly outline your experience and why you are interested in this Fellowship project (200 words) and (ii) attach a brief cv (max 2 pages). For more information about the COSA Cancer Pharmacists Group visit our webpage. Please contact [email protected] if you need further details.